VistaGen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing medicines to treat diseases and disorders of the central nervous system. It focuses on depressive and social anxiety disorders. The company's lead product candidate is AV-101 that is in Phase II clinical trial for the treatment of chronic neuropathic pain, epilepsy, major depressive disorder (MDD), parkinson's disease levodopa-induced dyskinesia, and others; PH94B, a neuroactive nasal spray that is in Phase II clinical trial for social anxiety disorder (SAD) and Phase III cross over study for SAD, and Phase IIa clinical trial for generalized anxiety disorder; and PH10, a neuroactive nasal spray that is in Phase IIa clinical trial for MDD. VistaGen Therapeutics, Inc. has licensing, sublicensing, and collaboration agreements with Pherin Pharmaceuticals, Inc.; BlueRock Therapeutics, LP; and Cato Research Ltd. The company also has agreement with Nuformix plc to develop novel c